Details for New Drug Application (NDA): 050297
✉ Email this page to a colleague
NDA 050297 describes ERYPED, which is a drug marketed by Azurity and is included in two NDAs. It is available from four suppliers. Additional details are available on the ERYPED profile page.
The generic ingredient in ERYPED is erythromycin ethylsuccinate. There are one hundred and three drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the erythromycin ethylsuccinate profile page.
The generic ingredient in ERYPED is erythromycin ethylsuccinate. There are one hundred and three drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the erythromycin ethylsuccinate profile page.
Summary for 050297
| Tradename: | ERYPED |
| Applicant: | Azurity |
| Ingredient: | erythromycin ethylsuccinate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 050297
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, CHEWABLE;ORAL | Strength | EQ 200MG BASE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, CHEWABLE;ORAL | Strength | EQ 200MG BASE | ||||
| Approval Date: | Jul 5, 1988 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
